INTRODUCTION: @entity2213 showed activity in 50 @entity3580 @entity1 treated within a Phase II study. In that study, 70% of @entity1 remained with @entity66 ( @entity66 ), median progression free survival (PFS) was 9 months and median @entity1349 ( @entity1349 ) was 34 months. We now report on a retrospective series of @entity6006 / @entity3820 positive advanced @entity3580 @entity1 treated with @entity2213 as a single agent within a compassionate-use programme at Istituto Nazionale Tumori, Milan, Italy (INT) between August 2002 and November 2010, when the programme was closed. METHODS: 48 @entity1 were consecutively treated with @entity2213 800 mg/d. All @entity1 had inoperable and progressive disease before starting @entity2213 . Demographics, treatment duration, @entity137 and response rate by Response Evaluation Criteria in @entity5 (RECIST) were retrospectively recorded. RESULTS: The median duration of therapy was 7 months (1-46.5). No @entity1 is on therapy at present. 46 @entity1 were evaluable for response. No partial responses were detected. Best response was: @entity66 34 (74%), @entity74 (26%). At a median follow-up of 24.5 months (0.5-117), median PFS was 9.9 months (95% confidence interval (CI) 6.7-13). Eight @entity1 (16.5%) remained on therapy >18 months and 10 @entity1 (21%) remained progression-free >18 months. Median @entity1349 was 30 months (95% CI 20-40), with 24 (50%) @entity1 dead at the time of the present analysis. CONCLUSIONS: We confirm the activity of @entity2213 in locally advanced and metastatic @entity3580 , in terms of >70% @entity5 growth arrest in previously progressive @entity1 . Median duration of response lasted almost 10 months, with >20% of @entity1 progression-free at 18+ months.

XXXX in advanced @entity3580 : A retrospective case series analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity66 :: ('MESH:D004194', 'Disease') :: ['SD', 'stable disease'] @entity6006 :: ('5155', 'Gene') :: ['PDGFB'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Solid Tumors', 'tumour'] @entity3820 :: ('5159', 'Gene') :: ['PDGFRB'] @entity3580 :: ('MESH:D002817', 'Disease') :: ['chordoma'] @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease 12'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib', 'Imatinib'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity2213 :: (MESH:C097613,Chemical) :: ['Imatinib']
